INTRODUCTION
Anemia of end-stage renal disease can be managed relatively successfully by recombinant human erythropoietin (EPO). Serum ferritin concentration and iron saturation ratio are among the two most commonly used markers of iron status in maintenance dialysis patients. 1 According to National Kidney Foundation (NKF) kidney disease and dialysis outcome quality initiative (K/DOQI) guidelines, the iron administration should be withheld for a serum ferritin level > 800 ng/mL in these patients, since such high ferritin levels may reflect iron overload. 2 However, serum ferritin is also an acute phase reactant and can be increased in inflammation. [3] [4] [5] Inflammation is quite common in maintenance dialysis patients, and its prevalence among maintenance hemodialysis (MHD) patients may be as high as 40 to 60%. Hence, it is quite possible that high levels of serum ferritin are engendered by inflammation independently of iron stores. 6 However, it is not clear whether serum ferritin is indeed significantly increased in inflammation at different levels of body iron in dialysis patients. Moreover, inflammation is closely related to protein-energy malnutrition in dialysis patients, and the simultaneous combination of these two conditions, also referred to as 'malnutritioninflammation complex syndrome' (MICS), is observed frequently in dialysis patients. 6 Over past 15 years, there has been an exponential growth of knowledge in inflammation in CKD and end stage renal disease (ESRD), which laid to evaluation in our perception of inflammation as a novel risk factor for morbidity and mortality associated with CKD. 7 Although the emergence of erythropoietin stimulating agents has a revolution the anemia management of CKD, 8 strategies to assess iron status have remained indistinct.
Ferritin though a reliable marker of body irons status, 9 is also known to be influenced by non-iron related conditions such as inflammation, malnutrition, liver diseases, infection and malignancies.
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MATERIALS AND METHODS
This study was a prospective, cross-sectional type. It was conducted between 15th September 2015 to 31st August 2017 in University Medical College with tertiary care hospital. The study was approved by the institutional ethics community. The study group was comprised of a total of 240 participants. They were divided into three groups as follows:
Group I: CKD on Hemodialysis with Iron/EPO Therapy
Total of 80 cases of CKD on hemodialysis receiving Iron/ EPO therapy.
Group II: CKD on Hemodialysis without Iron/EPO Therapy
Total of 80 cases of CKD on hemodialysis not receiving Iron/EPO therapy. The diagnosis of CKD was based on their history, clinical examination and laboratory findings. These cases were from both the outpatient and inpatient departments of the hospital.
Group III: Healthy Controls
Total of 80 age and gender-matched healthy individuals visiting the outpatient department of the hospital for a routine check-up.
Inclusion Criteria
Total 240 participants above 40 to 65 years of both genders were enrolled. One-hundred and sixty cases were CKD on hemodialysis with or without Iron/EPO therapy.
Exclusion Criteria
Participants suffering from known disorders/diseases like:
• Cardiac, hepatic and other systemic diseases.
• Any endocrinological abnormalities like thyroid disorders, etc. • H/O or clinical evidence of hemochromatosis.
• H/O drug or alcohol abuse.
All participants after their written informed consent underwent detailed physical and clinical examination. About 3 mL of blood sample was collected by venepuncture with all aseptic precautions in plain and ethylenediaminetetraacetic acid (EDTA) vacutainers. After one hour, the serum was separated from plain vacutainer by centrifugation at 2500 rpm for 5 minutes at room temperature. Serum was ensured to be free from hemolysis and turbidity. The whole blood collected in EDTA vacutainer was used for estimation of hemogram (Coulter LH750).
A separated serum sample was subjected towards estimation of parameters on different analysers (Table 1) . 
OBSERVATIONS AND RESULTS
The serum ferritin levels were significantly elevated in group I (1957.6 ± 714.1) and group II (1063.5 ± 478.6) as compared to group III (101.21 ± 60.29) ( Table 2 ). The CRP levels were significantly elevated in group I (104.6 ± 70.8) and group II (74.9 ± 55.8) as compared to group III (3.7 ± 0.9) ( Table 2) , Total leukocyte count was significantly elevated in group II (11669.88 ± 6200.82) as compared with group I (8087.50 ± 3697.36) and group III (7372.45 ± 1833.22). (Table 2) .
Hemoglobin concentration was significantly decreased in group I (9.42 ± 1.48) and group II (9.31 ± 1.83) as compared with group III (13.65 ± 9.78). Serum iron levels were significantly decreased in group I (66.17 ± 44.85)and group II (60.28 ± 44.35) as compared with group III (85.45 ± 42.91).
Serum TIBC levels were significantly decreased in group I (184.24 ± 77.12) and group II (174.24 ± 68.24) as compared with group III (322.95 ± 77.93) ( Table 3) .
We also found statistically significant positive correlation of serum ferritin levels with CRP (r-value: 0.531, p-value <0.01) and negative correlation of serum ferritin levels with TIBC (r-value 0.463 and p-value: < 0.001) ( Table 4) . We established a cutoff value of serum ferritin > 985 ng/mL in group I which may be associated with inflammation rather than iron overload (Table 5 and Graph 1).
IJMB
DISCUSSION
The finding of our study indicates, significant positive correlation of markers of inflammation that is both serum ferritin and CRP (Fig. 1) . A significant decrease in markers of iron status (indicated by low iron, TIBC and hemoglobin levels) are per various other studies. [15] [16] The finding of our study indicates, significant positive correlation of markers of inflammation that is both serum ferritin and CRP. A significant decrease in markers of iron status (indicated by low iron, TIBC and hemoglobin levels) are per various other studies. [15] [16] [17] Therefore it is necessary to establish a cutoff level serum ferritin in patients of CKD on hemodialysis receiving iron/EPO therapy.
We established a cutoff value of serum ferritin > 985 ng/mL in group I which may be associated with inflammation rather than Iron overload. Figure 1 17,18 depicts the causes and consequences of inflammation in chronic kidney disease. Inflammation mediates the processes of monocyte influx, the proliferation of macrophages and matrix expansion, and results in glomerulosclerosis and tubulointerstitial injury which may further exacerbate kidney injuries. 18, 19 However, Roger's JT 20 stated that IL-1β induces ferritin gene expression by translational control of its messenger ribonucleic acid (mRNA).The inflammatory induction to occur of ferritin requires the background presence of cellular iron. Without adequate iron stores, serum ferritin is low and does not correlate with inflammation. 21 Therefore as per their study findings with enough iron, serum ferritin is a marker of both iron storage and inflammation. However, this is in contradiction with our findings.
Strengths and Limitation of Our Study
Strengths of our study: Cross-sectional study design, Strict adherence to inclusion and exclusion criteria's and use of sensitive methods for the determination of serum ferritin, serum CRP, TLC, serum iron, and TIBC levels. Limitation of our study: We have not taken in consideration the dietary intake of iron, status of other markers of inflammation like interleukins-6 (ILs-6), tumor necrosis factor-α and hs-CRP (a better measure than CRP) along with ferritin.
CONCLUSION
The significant increase in serum ferritin levels in patients of CKD on hemodialysis, may not always reflect iron overload.
This rise may be an inflammatory response as indicated by the significant positive correlation of serum ferritin with C-reactive protein and decreased iron, TIBC, and hemoglobin.
The cutoff value of serum ferritin > 985 ng/mL in group I may be associated with inflammation rather than iron overload.
The presence of inflammation may be responsible for erythropoietin resistance as documented by previous studies.
Strategies to dissociate inflammation from iron metabolism to mitigate the co founding impact of inflammation on the iron to improve the responsiveness of iron and EPO therapy may improve management of anemia in CKD.
Future Scope
Longitudinal cross sectional cohort studies are required to observe the effect of hyperferritinemia with associate morbidity and mortality in patients of CKD.
To explore the potential therapeutic modalities for administrating anti cytokine agents which may prove useful to optimize EPO responsiveness.
